Recent studies also suggest that BRAF/MEK inhibition can enhance tumor immunogenicity by increasing the presentation of tumor antigens, providing further synergy with ICIs (Razavi et al., 2021; Ghasemi et al., 2024). The gene discussed is BRAF; the disease is neoplasm.